BIO-Europe 2025: Valneva's partner Pfizer has been running a key trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year
- Nov 3, 2025
- 1 min read
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine license.
Coverage brought to you by:
.png){kind=logo}